• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    4/8/22 2:00:17 PM ET
    $BCRX
    $BCYC
    $CCCC
    $GNCA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCRX alert in real time by email

     

    Gainers

    • Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume of 9.3 million, which is 1477.4% of its average full-day volume over the last 100 days. The company's market cap stands at $18.0 million.
    • Exicure (NASDAQ:XCUR) shares rose 21.72% to $0.25. Trading volume for this security as of 13:31 EST is 50.6 million, which is 399.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $31.2 million.
    • Lyra Therapeutics (NASDAQ:LYRA) shares moved upwards by 16.31% to $5.03. Trading volume for Lyra Therapeutics's stock is 4.7 million as of 13:31 EST. This is 17197.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $65.3 million.
    • Bicycle Therapeutics (NASDAQ:BCYC) shares rose 16.27% to $43.87. Bicycle Therapeutics's stock is trading at a volume of 808.0K shares as of 13:31 EST. This is 335.4% of its average full-day volume over the last 100 days. The company's market cap stands at $1.2 billion.
    • Nurix Therapeutics (NASDAQ:NRIX) shares moved upwards by 13.8% to $15.09. As of 13:31 EST, Nurix Therapeutics's stock is trading at a volume of 315.9K, which is 70.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $676.8 million. As per the press release, Q1 earnings came out yesterday.
    • Ikena Oncology (NASDAQ:IKNA) stock increased by 13.62% to $7.96. Ikena Oncology's stock is trading at a volume of 93.2K shares as of 13:31 EST. This is 70.5% of its average full-day volume over the last 100 days. The company's market cap stands at $287.6 million.

    Losers

    • Kaleido Biosciences (NASDAQ:KLDO) shares decreased by 69.9% to $0.45 during Friday's regular session. Trading volume for this security as of 13:31 EST is 8.1 million, which is 8174.5% of its average full-day volume over the last 100 days. The company's market cap stands at $18.9 million.
    • Genocea Biosciences (NASDAQ:GNCA) stock decreased by 51.71% to $0.63. Genocea Biosciences's stock is trading at a volume of 1.0 million shares as of 13:31 EST. This is 642.2% of its average full-day volume over the last 100 days. The company's market cap stands at $36.8 million.
    • C4 Therapeutics (NASDAQ:CCCC) stock decreased by 48.83% to $11.72. The current volume of 590.5K shares is 105.5% of C4 Therapeutics's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $571.2 million.
    • Rubius Therapeutics (NASDAQ:RUBY) stock declined by 41.86% to $3.41. As of 13:31 EST, Rubius Therapeutics's stock is trading at a volume of 2.6 million, which is 341.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $307.2 million.
    • BioCryst Pharmaceuticals (NASDAQ:BCRX) stock decreased by 37.39% to $11.2. Trading volume for this security as of 13:31 EST is 27.0 million, which is 669.2% of its average full-day volume over the last 100 days. The company's market cap stands at $2.0 billion.
    • Nutex Health (NASDAQ:NUTX) shares decreased by 25.05% to $9.28. Trading volume for Nutex Health's stock is 972.4K as of 13:31 EST. This is 113.8% of its average full-day volume over the last 100 days. The company's market cap stands at $5.9 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BCRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCRX
    $BCYC
    $CCCC
    $GNCA

    CompanyDatePrice TargetRatingAnalyst
    BioCryst Pharmaceuticals Inc.
    $BCRX
    2/18/2026$17.00Outperform
    Evercore ISI
    Nurix Therapeutics Inc.
    $NRIX
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    C4 Therapeutics Inc.
    $CCCC
    12/2/2025Buy
    TD Cowen
    Nurix Therapeutics Inc.
    $NRIX
    11/24/2025$30.00Buy
    Truist
    Bicycle Therapeutics plc
    $BCYC
    11/24/2025$19.00Hold
    Truist
    Bicycle Therapeutics plc
    $BCYC
    10/31/2025$11.00Outperform → Sector Perform
    RBC Capital Mkts
    Nurix Therapeutics Inc.
    $NRIX
    10/21/2025$24.00Outperform
    Mizuho
    BioCryst Pharmaceuticals Inc.
    $BCRX
    10/15/2025$30.00Buy
    TD Cowen
    More analyst ratings

    $BCRX
    $BCYC
    $CCCC
    $GNCA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 7, 2021 - Coronavirus (COVID-19) Update: September 7, 2021

    For Immediate Release: September 07, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Kaleido Biosciences, Inc. for not complying with federal laws and regulations, including laws and regulations to protect individuals participatin

    9/7/21 4:11:11 PM ET
    $KLDO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    $BCYC
    $CCCC
    $GNCA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT

    The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com KING OF PRUSSIA, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th, 2026. Mr. Bitterman

    3/10/26 7:59:39 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

    The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.comKing of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th, 2026. Mr. Bit

    3/10/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCRX
    $BCYC
    $CCCC
    $GNCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Milne Jill C. was granted 528 shares, increasing direct ownership by 4% to 15,382 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    3/3/26 4:36:58 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Stonehouse Jon P was granted 421 shares, exercised 305,995 shares at a strike of $3.22 and returned $2,643,797 worth of shares to the company (305,995 units at $8.64), increasing direct ownership by 0.03% to 1,323,850 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    3/3/26 4:34:13 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Milano Vincent was granted 848 shares, increasing direct ownership by 0.93% to 92,067 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    3/3/26 4:30:55 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    $BCYC
    $CCCC
    $GNCA
    SEC Filings

    View All

    $BCRX
    $BCYC
    $CCCC
    $GNCA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BCRX
    $BCYC
    $CCCC
    $GNCA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form S-8 filed by Nutex Health Inc.

    S-8 - Nutex Health Inc. (0001479681) (Filer)

    3/10/26 11:35:55 AM ET
    $NUTX
    Real Estate

    SEC Form 8-K filed by Nurix Therapeutics Inc.

    8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

    3/6/26 4:40:45 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Nurix Therapeutics Inc.

    424B5 - Nurix Therapeutics, Inc. (0001549595) (Filer)

    3/6/26 4:38:38 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evercore ISI resumed coverage on BioCryst Pharma with a new price target

    Evercore ISI resumed coverage of BioCryst Pharma with a rating of Outperform and set a new price target of $17.00

    2/18/26 8:21:17 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nurix Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00

    1/8/26 8:12:12 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on C4 Therapeutics

    TD Cowen initiated coverage of C4 Therapeutics with a rating of Buy

    12/2/25 8:23:26 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Bates Jon Christian bought $102,532 worth of shares (750 units at $136.71), increasing direct ownership by 15% to 5,638 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    11/28/25 2:11:24 PM ET
    $NUTX
    Real Estate

    $BCRX
    $BCYC
    $CCCC
    $GNCA
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

    SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger

    11/10/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

    King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to his new role as Lead Independent Director. He was with JP Morgan for over 27 years, both in M&A and leading the Health Group in investment banking for his last 12 years there. Mr. Deming was appointed

    10/31/25 10:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCRX
    $BCYC
    $CCCC
    $GNCA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

    SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    12/17/24 6:46:27 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCRX
    $BCYC
    $CCCC
    $GNCA
    Financials

    Live finance-specific insights

    View All

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

    —Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025)— —Record GAAP and non-GAAP operating profit for full year 2025— —Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million— —Received FDA approval for ORLADEYO oral pellets for patients with HAE Aged 2 to <12 Years— —Completed Acquisition of Astria Therapeutics— RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the full year ended December 31, 2025, an

    2/26/26 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate